Physician profile
Laura E Mizell
NPI 1457892648
$9,294.11
in general payments reported to CMS, 2019-2025
42 companies · $2,179 in 2025
The $2,179 reported for 2025 was more than what 94% of Family Health providers received nationally (typical 2025 total: $209).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,316 · 2022: $1,000 · 2023: $1,858 · 2024: $1,943 · 2025: $2,179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,978.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,524.72 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $920.23 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $821.79 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $686.47 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $656.20 | 2021-2025 | Jardiance, Stiolto Respimat, Tradjenta |
| Pfizer INC. | $644.43 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $398.47 | 2023-2025 | Gemtesa |
| Abbvie INC. | $347.81 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $323.33 | 2021-2025 | |
| Amgen INC. | $289.40 | 2021-2025 | Repatha, Otezla, Repatha |
| Paratek Pharmaceuticals, INC. | $255.00 | 2021-2025 | Nuzyra |
| Takeda Pharmaceuticals U.S.A., INC. | $202.57 | 2021-2024 | Trintellix |
| Dexcom, INC. | $189.29 | 2021-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $183.80 | 2021 | |
| Exact Sciences Corporation | $170.53 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Mizell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.